Pneumococcal Vaccines: Advances, Challenges, and Future Directions

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccines against Tropical and other Infectious Diseases".

Deadline for manuscript submissions: 15 July 2026 | Viewed by 8

Special Issue Editor


E-Mail Website
Guest Editor
Laboratório de Biologia Molecular de Microrganismos, Universidade São Francisco, Bragança Paulista 12916-900, Brazil
Interests: Streptococcus pneumoniae; vaccines; recombinant proteins; complement system; immune response

Special Issue Information

Dear Colleagues,

Streptococcus pneumoniae is a leading cause of morbidity and mortality worldwide. The global spread of antimicrobial resistance (AMR) further complicates this issue, leading to a significant increase in treatment failures. In this context, vaccination becomes a critical tool to combat AMR and reduce disease, particularly among vulnerable groups like children and the elderly. While approved pneumococcal conjugate vaccines (PCVs) have proven highly effective, their success has been hindered by serotype replacement—a consequence of the selective pressure exerted by the vaccine on a diverse pool of existing serotypes. This phenomenon necessitates frequent updates to the vaccine to include additional serotypes. However, implementing these updated formulations in low-resource settings is often challenging, resulting in uneven vaccine distribution and contributing to the ongoing spread of disease. To address these limitations, significant research is underway to develop serotype-independent vaccines, including formulations based on well-characterized conserved protein antigens and novel candidates. This Special Issue will explore the leading candidates under investigation and provide critical analyses of preclinical and clinical findings. Key topics will encompass the following:

  • Vaccine development from early-stage discovery to Phase 3 clinical trials;
  • The application and limitations of various animal models;
  • The crucial role of novel adjuvants and delivery systems.

This collection aims to provide a comprehensive overview of the field and inform future decisions regarding the development of next-generation pneumococcal vaccines and public health strategies.

We look forward to receiving your contributions.

Prof. Dr. Michelle Darrieux
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Streptococcus pneumoniae
  • antimicrobial resistance (AMR)
  • vaccination
  • pneumococcal conjugate vaccines (PCVs)
  • serotype replacement
  • serotype-independent vaccines
  • protein antigens
  • reverse vaccinology
  • clinical trials
  • vaccine adjuvants

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers

This special issue is now open for submission.
Back to TopTop